6472 Share Price Performance
NT$0
-617.61 (-100.00%)
Price NT$0
Fair ValueNT$530.00
Share Pricen/a
Bora Pharmaceuticals Co., LTD. Stock Price
- 2 Narratives written by author
- 0 Comments on narratives written by author
- 9 Fair Values set on narratives written by author
6472 Community Narratives
AN
Fair Value NT$530 7.3% undervalued intrinsic discount
CDMO Onshoring And Specialty Neurology Mix Will Support Stable Long Term Performance
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value NT$788.87 37.7% undervalued intrinsic discount
US CDMO Expansion And Specialty Focus Will Strengthen Position
0users have liked this narrative
0users have commented on this narrative
7users have followed this narrative
CDMO Onshoring And Specialty Neurology Mix Will Support Stable Long Term Performance
Catalysts About Bora Pharmaceuticals Bora Pharmaceuticals is a global pharmaceutical CDMO and specialty pharma company that provides development, manufacturing and commercial solutions across multiple dosage forms. What are the underlying business or industry changes driving this perspective?Read more
0
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
NT$530
7.3% undervalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
13.5% p.a.
Profit Margin
21.06%
Future PE
12.03x
Price in 2028
NT$617.58
US CDMO Expansion And Specialty Focus Will Strengthen Position
Key Takeaways Operational recovery and strategic expansion in higher-value pharmaceuticals and CDMO capacity position Bora for stronger margins and recurring, long-term revenue growth. Enhanced client base, project wins, and operational efficiencies increase visibility, stability, and sustained profitability for future earnings.Read more
10
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
7users have followed this narrative
AN
NT$788.87
37.7% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
21.19% p.a.
Profit Margin
20.52%
Future PE
15.03x
Price in 2028
NT$915.27
Trending Discussion
Recently Updated Narratives
AN
CDMO Onshoring And Specialty Neurology Mix Will Support Stable Long Term Performance
Fair Value: NT$530 7.3% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
6472: Improved Profit Margins Will Support Stronger Long Term Performance
Fair Value: NT$788.87 37.7% undervalued intrinsic discount
7 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Bora Pharmaceuticals Co., LTD. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- 34.16
- 37.83%
- 20.11%
- 119.5%
About 6472
- Founded
- 2007
- Employees
- n/a
- CEO
- WebsiteView website
Bora Pharmaceuticals Co., LTD. engages in contract development, manufacture, and sale of pharmaceuticals in Europe, the United States, Taiwan, and internationally. The company operates through Sales, CDMO, and Other segments. It manufactures and sells generic, brand, and over the counter (OTC) drugs. The company also offers contract development and manufacturing services and technical services for the development of pharmaceutical products. In addition, it provides Western pharmaceuticals, including central nervous system medications, antibiotics, and gastrointestinal medications; and nutritional and vitamin supplements, physical recovery, and health care products. The company sells its products directly to clinics, pharmacies, pharmacy chains, and drug stores, as well as through distributors to medical centers, corporate and public hospitals, and regional and district hospitals. Bora Pharmaceuticals Co., LTD. was incorporated in 2007 and is based in Taipei City, Taiwan.
